Published in:
Volume 3 / Year 2014 / Issue 1

The biosimilar name debate: what’s at stake for public health

Page: 10-2

Abstract: As the number of innovator biologics and biosimilars increases worldwide, a growing debate has focused on how these products should be named. The simple concept of a name can… Read More »

Biosimilar monoclonal antibodies approved for use in the EU

Author(s): ,
Page: 9-10

Abstract: Two biosimilar TNF-alfa monoclonal antibody (mAb) products were approved for clinical use in the European Union on 10 September 2013, following a positive opinion by the Committee for Medicinal… Read More »

Go Back Print